Buy Like Buffett
Watchlist

Flagship explainer

How Zomedica Corp. makes its money

Start with a dollar of revenue and follow what the filing says remains.

revenueBranching filed flows with values and percentages directly labeled. Missing filing concepts are omitted rather than estimated.Revenue$32M · 100%Cost of revenue$10.4M · 32%Gross profit$21.7M · 68%Operating income−$84.4M · −263%Income before tax−$82.1M · −256%Income tax−$278000 · −1%Net income−$81.9M · −256%As of 2025-12-31 · 2 SEC filing sourcesBuy Like Buffett · buylikebuffett.com

Honest partial: the filing did not provide a normalized tag for Research and development, Selling, general and administrative; those components are omitted, not plugged.

Table alternative
Filed lineValue% of revenueSource
$32M100%
  • 10-K · FY 2025Filing detailsAccession 0001104659-26-028450 · filed Mar 16, 2026
Cost of revenue$10.4M32%
  • 10-K · FY 2025Filing detailsAccession 0001104659-26-028450 · filed Mar 16, 2026
$21.7M68%
  • 10-K · FY 2025Filing detailsAccession 0001104659-26-028450 · filed Mar 16, 2026
−$84.4M−263%
  • 10-K · FY 2025Filing detailsAccession 0001104659-26-028450 · filed Mar 16, 2026
Income before tax−$82.1M−256%
  • 10-K · FY 2025Filing detailsAccession 0001104659-26-028450 · filed Mar 16, 2026
Income tax−$278000−1%
  • 10-K · FY 2025Filing detailsAccession 0001104659-26-028450 · filed Mar 16, 2026
−$81.9M−256%
  • 10-K · FY 2025Filing detailsAccession 0001104659-26-028450 · filed Mar 16, 2026
Source:
  • 10-K · FY 2025Filing detailsAccession 0001104659-26-028450 · filed Mar 16, 2026
· event Dec 31, 2025 · retrieved Oct 16, 2026 · annual-row source set
Embed this chart

View the full Zomedica Corp. analysis at Buy Like Buffett